Fusion Medical
This article was originally published in The Gray Sheet
Executive Summary
Surgical sealant developer raises $8 mil. in a private equity placement with Alloy Ventures, the State of Wisconsin Investment Board, and the Asset Management Company. Proceeds will go toward commercialization of the firm's FloSeal and Proceed hemostatic sealants. Approximately 2.7 mil. shares were sold at $2.93 each, which is the average closing price of Fusion stock over the ten days preceding the April 9 completion of the financing. In addition, each investor received a warrant for the purchase of up to an additional 25% of the total shares purchased at $3.66 per share, or 125% of the purchase price
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.